Enanta Pharmaceuticals, Inc.ENTANASDAQ
Loading
Revenue ContractionContracting
Percentile Rank29
3Y CAGR-8.8%
5Y CAGR-11.8%
Studio
Year-over-Year Change

Total revenue from sales of goods and services

3Y CAGR
-8.8%/yr
vs -19.6%/yr prior
5Y CAGR
-11.8%/yr
Consistent
Acceleration
+10.8pp
Accelerating
Percentile
P29
Within normal range
vs 5Y Ago
0.5x
Contraction
Streak
7 yr
Consecutive declineContracting
PeriodValueYoY Change
2025$65.32M-3.4%
2024$67.64M-14.6%
2023$79.20M-8.1%
2022$86.16M-11.2%
2021$97.07M-20.7%
2020$122.47M-40.3%
2019$205.20M-0.7%
2018$206.63M+101.0%
2017$102.81M+16.5%
2016$88.27M-